Autres langues Biosergen AB

Actions

BIOSGN

SE0016013460

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 24/01/2025			Varia. 5j.	Varia. 1 janv.
0,4950 ^SEK	+1,85%		-4,81%	-6,60%

20/12	Biosergen AB accepte une augmentation accélérée de la dose dans la deuxième cohorte de l'essai clinique en cours	CI
04/12	Biosergen émet des actions après l'exercice de bons de souscription pour un montant de 45 millions de couronnes suédoises	MT

Autres langues

Biosergen Agrees to Accelerated Dosing Escalation in Ongoing Second Cohort of Clinical Trial	20/12
Biosergen AB Agrees to Accelerated Dosing Escalation in Ongoing Second Cohort of Clinical Trial	20/12
Biosergen resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO3	05/12
Biosergen to Issue Shares After SEK45 Million Exercise of Warrants	04/12
Biosergen AB conducts a directed share issue to underwriters in connection with the completed exercise period for warrants of series TO3	03/12
Biosergen AB receives approximately SEK 44.9 million through warrants of series TO3	03/12
Biosergen Doses First Patients in Second Cohort of BSG005 Clinical Trial for Life-Threatening Fungal Infections	26/11
Biosergen AB Doses First Patients in Second Cohort of BSG005 Clinical Trial for Life-Threatening Fungal Infections	26/11
The last day of trading with the warrants of series TO3 in Biosergen AB is today, November 26, 2024	26/11
Biosergen Releases Interview with Principal Investigator Dr. Pawan Singh on Drug-Resistant Fungal Infections and BSG005	21/11
Biosergen Secures SEK45 Million via Warrant Exercise	18/11
Biosergen has secured 100 percent of the warrants of series TO3 approximately SEK 44.9 million	18/11
The exercise price for the warrants of series TO3 in Biosergen AB has been determined to SEK 0.49	18/11
Research update Biosergen: Promising interim data as BSG005 saves lives	14/11
BioStock: Biosergen discusses positive results in patients with deadly fungal infections	13/11
Biosergen publishes interim report for third quarter 2024	08/11
Biosergen AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	08/11
Biosergen Announces Safety Committee Approval to Proceed with Dose Escalation in Second Cohort for BSG005 Clinical Trial	07/11
Biosergen to Proceed with Dose Escalation in Second Cohort for BSG005 Clinical Trial	07/11
BioStock: Biosergen's CEO: "I'm optimistic that we may cure patients"	06/11
Biosergen Completes First Cohort of BSG005 Clinical Trial, Shows Promising Potential in Drug-Resistant Fungal Infections	31/10/24
Biosergen Completes First Cohort of BSG005 Clinical Trial, Shows Promising Potential in Drug-Resistant Fungal Infections	31/10/24
BioStock: Biosergen advances BSG005 antifungal drug candidate trial	18/10/24
Biosergen Completes Enrollment of First Cohort in BSG005 Proof-of-Concept Trial	07/10/24
Biosergen AB Completes Enrollment of First Cohort in Biosergen Proof-Of-Concept Trial	07/10/24

Devenez membre pour accéder à plus d'actualités

Inscription 100% Gratuite

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Biosergen AB

Actions

BIOSGN

SE0016013460

Recherche biotechnologique et médicale

Autres langues

Filtres